Jason Hlozek

Jason Hlozek

Auto-generated profile, based on publicly available information

Jason Hlozek

Department of Chemistry and Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Cape Town, South Africa

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
GTGemma Turon
Gemma Turon
JHJason Hlozek
Jason Hlozek
JWJohn G. Woodland
John G. Woodland
AKAnkur Kumar
Ankur Kumar
KCKelly Chibale
Kelly Chibale
MDMiquel Duran-Frigola
Miquel Duran-Frigola
Streamlined data-driven drug discovery remains challenging, especially in resource-limited settings. We present ZairaChem, an artificial intelligence (AI)- and machine learning (ML)-based tool for quantitative structure-activity/property relationship (QSAR/QSPR) modelling. ZairaChem is fully automated, requires low computational resources and works across a broad spectrum of datasets. We describe an end-to-end implementation at the H3D Centre, the leading integrated drug discovery unit in Africa, at which no prior AI/ML capabilities were available. By leveraging in-house data collected over a decade, we have developed a virtual screening cascade for malaria and tuberculosis drug discovery comprising 15 models for key decision-making assays ranging from whole-cell phenotypic screening and cytotoxicity to aqueous solubility, permeability, microsomal metabolic stability, cytochrome inhibition, and cardiotoxicity. We show how computational profiling of compounds, prior to synthesis and testing, can inform progression of frontrunner compounds at H3D. This project is a first-of-its-kind deployment at scale of AI/ML tools in a research centre operating in a low-resource setting.

15 December 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
GTGemma Turon
Gemma Turon
JHJason Hlozek
Jason Hlozek
JWJohn G. Woodland
John G. Woodland
KCKelly Chibale
Kelly Chibale
MDMiquel Duran-Frigola
Miquel Duran-Frigola
We present ZairaChem, an artificial intelligence (AI)- and machine learning (ML)-based tool to train small-molecule activity prediction models. ZairaChem is fully automated, requires low computational resources and works across a broad spectrum of datasets, ranging from whole-cell growth inhibition assays to drug metabolism properties. The tool has been implemented end-to-end at the Holistic Drug Discovery and Development (H3D) Centre, the leading integrated drug discovery unit in Africa, at which no prior AI/ML capabilities were available. We have exploited in-house data collected from over a decade of drug discovery research in malaria and tuberculosis and built models to predict the outcomes of 15 key checkpoint assays. We subsequently deployed these models as a virtual screening cascade at an organisational scale to increase the hit rate of current experimental assays. We show how computational profiling of compounds, prior to synthesis and experimental testing, can increase the rate of progression by up to 40%. Moreover, we demonstrate that the approach can be applied to prioritise small molecules within a chemical series and to assess the likelihood of success of novel chemotypes, promoting efficient usage of limited experimental resources. This project is part of a first-of-its-kind collaboration between the H3D Centre, a research centre operating in a low-resource setting, and the Ersilia Open Source Initiative, a young tech non-profit devoted to building data science capacity in the Global South.

25 November 2025 in Communications Medicine
Verified
Journal Article
Open access
GTGemma Turon
Gemma Turon
JHJason Hlozek
Jason Hlozek
MDMiquel Duran-Frigola
Miquel Duran-Frigola
KCKelly Chibale
Kelly Chibale
JWJohn G. Woodland
John G. Woodland
Despite being rich in natural resources and scientific talent, Africa continues to bear a staggering infectious disease burden. Historically, health innovation on the continent has relied on international funding and has been constrained by limited infrastructure and the emigration of skilled professionals. Data science tools offer a promising alternative, typically requiring fewer costly resources than traditional empirical research, with the potential to empower African scientists to generate tangible and impactful health solutions for the continent. Rapid progress in data science is expected to transform infectious disease research; thus, it is encouraging that numerous African initiatives are already applying data science tools to tackling pressing unmet medical needs, particularly in drug discovery. These efforts include identifying novel therapeutic targets, predicting drug-like molecules and their synthesis, enhancing clinical trial success rates and preparing for future disease threats. This review examines the current landscape of data science in infectious disease drug discovery across Africa.